The startup, which has already raised more than half a billion dollars, released Phase 2 results that could position its drug ...

New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight ...

People with diabetes who were taking GLP-1 receptor agonist drugs such as tirzepatide and semaglutide had significantly lower rates of hospital readmission, wound re-opening and hematoma after surgery ...

Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...

Expanding volumes of data point to mechanisms beyond weight loss and blood sugar control that contribute to cardiovascular ...

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...

Ozempic has fast become a household name. In addition to helping people with diabetes manage their blood sugar levels, this ...

Weight-loss injection Mounjaro, or tirzepatide, will be rolled out on the NHS gradually over a 12-year period, starting this year.

Semaglutide is a synthetic version of a hormone known as GLP-1, which the body releases into the intestine when people eat food, as TODAY.com previously reported. It signals to the brain that you ...

Ozempic and Wegovy, made by Novo, are on track to become the world’s top-selling drugs by 2025. Yet in 2024, ‘Wegovy Wednesday’ had already become one of the biggest weight-loss trends to sweep the ...

Scientists believe the weight-loss jab's role in reducing inflammation in the body is key as this is common to other ...

The first medication for obstructive sleep apnea has been approved by the U.S. Food and Drug Administration (FDA). On Dec. 20 ...